Skip to main content
What types of page to search?

Alternatively use our A-Z index.

From laboratory to patient: Why manufacturing capability matters for long-acting medicines

Posted on: 2 October 2026 by Rebecca Derrick in LONGEVITY Blog

a global heat map with the blog title written over the top

Both the UK and US celebrate manufacturing around the same time of year, so we decided to talk about our Manufacturing Capabilities project at the same time.

In the UK, National Manufacturing Day is held on the last Thursday in September, and in the US Manufacturing Day is on the first Friday in October.

For both countries the day is an opportunity for manufacturing companies to open their doors and invite the pubic to see what goes on behind the scenes in modern manufacturing. This allows people to see career potentials, businesses to engage with future talent, and interested local communities to glimpse part of their purchasing behaviour that we rarely see.

National Manufacturing Day is an opportunity to showcase the diversity of a truly fascinating sector

The Centre of Excellence for Long-acting Therapeutics – Global Health (CELT Global Health), co-Directed by Professor Steve Rannard and Professor Andrew Owen, runs a project called Manufacturing Capability.

The project is funded by global health agency Unitaid and managed by CELT Global Health’s Dr Cameron Hogarth. The aim is to create a freely available global resource that shows what long-acting manufacturing capabilities exist in different contract pharmaceutical facilities across the world.

Many preventable or treatable diseases are not being prevented or treated effectively in low- and middle- income countries (LMICs). The excessive effort of overseeing the pill management for critical diseases leads to low medication adherence. This is part of the significant differences we see in disease impact in these regions.

While we are interested in developing long-acting medicines that could help address some of the challenges associated with current treatment regimens, we also need to think about what happens next:

How can these formulations be manufactured at the scale needed, and where can that manufacturing take place?

Local pharmaceutical manufacturing will be incredibly important to bridging the access gaps we see globally in medication availability. We spoke to Dr Hogarth about the purpose of the project.

What is the Manufacturing Capability project?

The Manufacturing Capability project is about understanding what manufacturing capability already exists and where it could support the production of long-acting therapeutics, particularly for LMIC markets.

This might sound straightforward, but finding the right manufacturing partner can be a significant challenge.

Long-acting therapeutics may be developed using different technologies and manufacturing processes.  While a manufacturer may already have equipment, facilities and expertise that could potentially be adapted for long-acting products, they may not have experience with these newer technologies or all of the specialised capabilities required for large-scale production.

At the same time, information about manufacturing organisations and their capabilities can be fragmented and difficult for medicine developers to find.

So, even when the science is ready, identifying who can actually make the medicine can become a barrier.

The Manufacturing Capability Project aims to help address this gap.

How are CELT Global Health addressing this?

Our approach is centred around understanding and connecting manufacturing capabilities.

CELT Global Health is assessing contract manufacturing organisations, with a particular focus on facilities and potential partners in LMICs. We are engaging with stakeholders to understand what they can currently produce, the technologies and equipment they have access to, and where their capabilities may be suitable for long-acting therapeutics.

This information can then be brought together to create a clearer picture of the global manufacturing landscape. With this, we aim to establish an open-access web resource that can be used by developers of long-acting medicines.

Rather than having developers start from scratch every time they need to identify a potential manufacturing partner, the resource will help them understand which organisations may have the capabilities needed for their particular product and target market.

In simple terms, we are helping to answer a question that is often overlooked:

We have developed this medicine – now, who can make it?

Why does this matter?

Ultimately, this project is about much more than manufacturing.

It is about access.

A medicine can only benefit a patient if it is available to them. For people living in LMICs, access to medicines can be affected by many different factors, including how medicines are produced, supplied and distributed.

Local manufacturing has the potential to play an important role in improving access to medicines. Building stronger manufacturing capacity could create opportunities to respond more effectively to local health needs and potentially reduce reliance on medicines being manufactured elsewhere and imported at higher cost.

For long-acting therapeutics, this is particularly important.

Long-acting medicines have the potential to reduce treatment burden by decreasing how frequently a person needs to take or receive their medication. This could be particularly valuable for conditions where long-term treatment can be difficult to maintain.

But the potential benefits of a long-acting medicine cannot be realised if the medicine cannot be produced at the scale, quality and cost needed to reach patients.

That means manufacturing needs to be considered from the beginning, rather than as something that happens at the very end of the development process.

What is the hopeful impact to global health?

The Manufacturing Capability Project is helping CELT Global Health look beyond the laboratory.

Our goal is to make it easier for developers of long-acting therapeutics to understand the manufacturing landscape and identify potential partners. By bringing together information about existing capabilities, we hope to support new collaborations and help strengthen local production capacity.

Ultimately, this could help long-acting medicines move one step closer to the people who need them.

Because innovation does not end when a medicine is developed.

The real impact comes when that medicine can be manufactured, made accessible and delivered to patients.

By understanding manufacturing capability today, we can help build the foundations for better access to long-acting therapeutics tomorrow.

 

#ManufacturingDay #MFGday

 


The Manufacturing Capability project is funded by global health agency Unitaid.

The Unitaid logo is the organisation name written above the words